Tumor Recurrence clinical trials

Explore recruiting tumor recurrence clinical trials.

Recruiting tumor recurrence studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tumor Recurrence trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Austria, Portugal, Netherlands, Greece, Belgium, Spain +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Unravelling the invisiBle infiltRating cOmponeNT Of glioblaStomA Using mRi USpio (BRONTOSAURUS)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification (NivoMela)

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

ETNA: Adjuvant pembrolizumab and chemotherapy or surveillance in Early Triple Negative breAst cancer with high stromal tumor-infiltrating lymphocytes (TILs) score

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Tumor Recurrence trials by city

Tumor Recurrence in Toronto Tumor Recurrence in Vancouver Tumor Recurrence in Montreal Tumor Recurrence in Calgary Tumor Recurrence in Edmonton Tumor Recurrence in Ottawa Tumor Recurrence in Winnipeg Tumor Recurrence in Quebec City Tumor Recurrence in Hamilton Tumor Recurrence in Kitchener Tumor Recurrence in London Tumor Recurrence in Halifax Tumor Recurrence in New York Tumor Recurrence in Los Angeles Tumor Recurrence in Chicago Tumor Recurrence in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease